Spero Therapeutics (NASDAQ:SPRO) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a research report sent to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.

SPRO has been the subject of a number of other research reports. Cantor Fitzgerald restated an overweight rating on shares of Spero Therapeutics in a report on Tuesday, August 6th. TD Cowen upgraded shares of Spero Therapeutics from a hold rating to a buy rating in a report on Tuesday, August 6th.

Spero Therapeutics Trading Up 0.8 %

SPRO opened at $1.30 on Thursday. The firm has a market capitalization of $70.19 million, a PE ratio of 3.02 and a beta of 0.62. Spero Therapeutics has a twelve month low of $0.99 and a twelve month high of $1.89. The firm’s 50-day moving average price is $1.32 and its 200 day moving average price is $1.43.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $10.20 million for the quarter, compared to the consensus estimate of $9.80 million. Spero Therapeutics had a net margin of 14.74% and a return on equity of 25.67%. During the same period in the previous year, the firm earned ($0.23) EPS. As a group, analysts predict that Spero Therapeutics will post -1.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SPRO. Renaissance Technologies LLC boosted its holdings in shares of Spero Therapeutics by 14.2% in the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock valued at $1,269,000 after buying an additional 121,492 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Spero Therapeutics by 40.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock valued at $1,392,000 after buying an additional 309,262 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Spero Therapeutics in the 1st quarter valued at $31,000. Murchinson Ltd. raised its position in Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after purchasing an additional 11,210 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Spero Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after purchasing an additional 9,675 shares during the last quarter. Institutional investors and hedge funds own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.